StockData
OptimizeRx Corp logo

OptimizeRx Corp (OPRX) stock analysis

OPRXNasdaqServices-Business Services, NECFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/3030% below fair value
$7.34−1.53 (-17.25%)

Close on Nov 13, 2026Market cap $138.26MP/E 28.2Yield –

StockData Score

Prices as of Nov 13, 2026How the score works

Value3Growth2Performance2Health4Dividend0

Mixed11 of 30 checks passed

OptimizeRx passes 11 of the 30 checks behind our score; 11 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
3/6
Growth
2/6
Past performance
2/6
Financial health
4/6
Dividend
0/6

What stands out

  • Margin of safety over 20%

    The price is 30.2% below fair value, more than the 20% cushion we look for.

  • Trading below fair value

    The share price of $7.34 is below our fair value estimate of $10.52.

  • Low debt

    Debt is 9.5% of shareholders' equity, under the 40% we consider low.

  • Revenue growing 10%+ a year

    Revenue grew 20.6% a year over the last three fiscal years.

What to watch

  • Return on equity under 15%

    Return on equity was 3.9% over the last twelve months and averaged -6.9% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 5.5%, below the 10% that usually covers the cost of capital.

  • Interest not well covered

    Operating income covers interest expense 3.1 times; we look for at least 5.

  • P/E above the industry

    OptimizeRx's P/E of 28.2 is above the Miscellaneous Business Services median of 25.6.

Valuation3/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E above the industry

    OptimizeRx's P/E of 28.2 is above the Miscellaneous Business Services median of 25.6.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B below the industry

    OptimizeRx's price-to-book of 1.03 is below the Miscellaneous Business Services median of 2.48.

  • Trading below fair value

    The share price of $7.34 is below our fair value estimate of $10.52.

  • Margin of safety over 20%

    The price is 30.2% below fair value, more than the 20% cushion we look for.

Growth2/6

  • Revenue growing 10%+ a year

    Revenue grew 20.6% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew -14.0% over the last twelve months; the Miscellaneous Business Services median is 9.8%.

  • Guidance lowered

    OptimizeRx lowered its fiscal year 2026 revenue outlook on May 12, 2026.

  • Gross margin improving

    Gross margin was 75.3% over the last twelve months, against 65.3% a year earlier.

Past performance2/6

  • Return on equity under 15%

    Return on equity was 3.9% over the last twelve months and averaged -6.9% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 5.5%, below the 10% that usually covers the cost of capital.

  • Return on equity below the industry

    OptimizeRx's return on equity of 3.9% is below the Miscellaneous Business Services median of 6.8%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was 5.3% over the last twelve months, against a 5-year average of -11.9%.

  • Net margin above the industry

    OptimizeRx's net margin of 5.3% is above the Miscellaneous Business Services median of 4.1%.

Financial health4/6

  • Low debt

    Debt is 9.5% of shareholders' equity, under the 40% we consider low.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 157% of total debt.

  • Interest not well covered

    Operating income covers interest expense 3.1 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 5.06 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 3.39; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    OptimizeRx has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$10.52

The share price is 30% below this estimate.

20%+ below
Near fair value
20%+ above
$7.34Price$10.52Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E25.6×–25.6×$6.6547%
EV/EBITDA15.5×–15.5×$13.5141%
P/B2.2×1.9×2.5×$15.5412%
Earnings powerleft out, too far from the others14.8% cost of equity––$1.93–
Fair value$10.52100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Miscellaneous Business Services median 25.6

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day
$1.81M
Value traded per 1% price move
$477.76K

Downside

High risk

Typical loss in a bad month
35.1%
Volatility (annualized)
71%
Sharpe ratio, 1 year
-0.84
Beta to the S&P 500 (5Y)
1.94

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

67.3%+11.6 pts over 5 years

Operating margin

10.7%+15.6 pts over 5 years

Net margin

4.7%+9.8 pts over 5 years

See a number that looks wrong?